Boston Scientific stock slips after Citi downgrade and cyberattack fallout
Published on 09/18/2026 at 15:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Boston Scientific stock (ISIN US10117L1017) traded around USD 43.55 on the New York Stock Exchange as of September 17, 2026, leaving the medical device group near its 52-week low after a series of setbacks and a fresh downgrade by Citigroup on September 17, 2026.
Citi downgrade highlights cyberattack risk
As Yahoo Finance reported on September 17, 2026, Citigroup cut its rating on Boston Scientific from Buy to Neutral and lowered its price target from USD 57 to USD 50, citing ongoing operational challenges following an August cyberattack and intensifying competition in key medical device markets.
According to Seeking Alpha on September 17, 2026, Citi argued that Boston Scientific is still contending with the aftermath of an August cyberattack and increased competition in several businesses, with the new USD 50 target implying roughly 14 percent upside from the September 16, 2026 closing price of USD 43.14.
Price pressure and proximity to 52-week low
Per Yahoo Finance data, Boston Scientific stock closed at USD 43.55 on September 17, 2026 on the New York Stock Exchange, down 0.82 percent from the prior session, with a prior close near USD 43.91 and a modest pre-market move to about USD 43.57 early on September 18, 2026.
As Investing.com noted on September 17, 2026, the stock recently traded at around USD 43.06, near a 52-week low of USD 42.20 and down 54 percent year to date, underscoring how far Boston Scientific stock has fallen compared with its levels at the start of 2026.
Guidance cuts and recent revenue growth
According to Yahoo Finance on September 17, 2026, Boston Scientific reduced its full-year 2026 organic revenue guidance in late July 2026 to a range of 5 percent to 6 percent growth, after previously signaling faster expansion in core product lines.
The same article states that total company organic sales grew 7 percent in the second quarter of 2026, at the top of the company’s guidance range for that period, providing a recent reference point where operational performance exceeded the updated full-year guidance range.
Analyst views diverge after cyberattack
Despite the downgrade from Citigroup, not all analysts have turned cautious. As Investing.com reported on September 17, 2026, TD Cowen reiterated a Buy rating on Boston Scientific stock with a price target of USD 56, even after lowering its estimates to reflect the second-half 2026 impact of the August 25, 2026 cyberattack.
In the same report, Investing.com highlighted that Stifel has maintained a Buy rating on Boston Scientific with a USD 60 price target, acknowledging ongoing disruptions but pointing to the company’s efforts to restore operations and its longer-term prospects.
Cybersecurity incident weighs on operations
According to Investing.com, Boston Scientific has been navigating a cybersecurity incident that disrupted its global operations, affecting information systems and business applications and temporarily impairing its ability to process and ship customer orders, with the company now reporting that major distribution centers are again operating at or above normal levels.
As Yahoo Finance summarized on September 17, 2026, Citigroup’s downgrade and reduced price target explicitly referenced the uncertain recovery path after these setbacks and slower-than-expected growth in core markets, factors that investors now need to weigh against the company’s progress in restoring its distribution network.
Stock valuation and option activity
On the valuation side, GuruFocus wrote on September 17, 2026 that its GF Value model places Boston Scientific’s fair value at about USD 107.27 versus a current price of USD 43.14, implying that the shares are approximately 59.8 percent undervalued according to that framework.
Derivatives traders are also active in the name. In a pre-market options report on September 18, 2026, Market Rebellion noted that Boston Scientific’s 30-day implied volatility stood at 38 compared with a 52-week range of 21 to 55, with a call-put ratio of 1.8 calls to 1 put and a particular focus on 25,000 contracts of December 75 calls trading at USD 0.10.
Closing snapshot for Boston Scientific stock
Based on New York exchange data referenced by major financial portals, Boston Scientific stock closed at about USD 43.55 on the New York Stock Exchange on September 17, 2026, roughly 2 percent below recent levels around USD 44.50 and close to its 52-week low near USD 42, with the move leaving the company’s market capitalization in the low tens of billions of USD and daily trading volume in the millions of shares.
Boston Scientific stock key data
- Company: Boston Scientific Corporation
- ISIN: US10117L1017
- Ticker: BSX
- Trading venue: New York Stock Exchange
- Price (as of September 17, 2026): 43.55 USD
- Market capitalization: low tens of billions USD (as of September 17, 2026)
- Sector / Industry: Health Care / Medical Devices
- Index membership: S&P 500
